- Home
- URGN vs CII Comparison
URGN vs CII Comparison
Compare URGN & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | URGN | CII |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 922.1M | 916.6M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | URGN | CII |
|---|---|---|
| Price | $19.24 | $22.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $29.29 | N/A |
| AVG Volume (30 Days) | ★ 697.0K | 97.9K |
| Earning Date | 06-10-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,128,000.00 | N/A |
| Revenue This Year | $119.37 | N/A |
| Revenue Next Year | $64.79 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.42 | $15.20 |
| 52 Week High | $30.00 | $26.17 |
Technical Indicators
Market Signals| Indicator | URGN | CII |
|---|---|---|
| Relative Strength Index (RSI) | 41.99 | 38.12 |
| Support Level | $18.65 | $21.11 |
| Resistance Level | $20.44 | $22.30 |
| Average True Range (ATR) | 1.59 | 0.26 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 32.02 | 16.79 |
Price Performance
Historical ComparisonAbout URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.